JERSEY CITY, N.J., Dec. 10, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX) today announced the pricing of its previously announced underwritten public offering of 38,888,889 shares of common stock and warrants to purchase up to 38,888,889 shares of common stock. Each share of common stock and warrant to purchase one share of common stock are being sold...
Category: News
SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants
JERSEY CITY, N.J., Dec. 9, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ : SCYX) today announced that it has commenced an underwritten public offering of shares of its common stock and warrants. In addition, SCYNEXIS expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and warrants...
Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General Meeting
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OR AN...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Dec. 02, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on November 29, 2019, the Company granted stock options and restricted stock units to one new employee of the Company. These awards were granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as...
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, Dec. 02, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 18,000 ordinary shares of Nabriva Therapeutics as inducements to 4 newly-hired...
Nabriva Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Gary Sender Chief Financial Officer and Francesco Lavino Chief Commercial Officer, will provide a company overview and...
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection
Topline results expected in Q1 2020 DUBLIN, Ireland and CHICAGO, Nov. 18, 2019 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced...
Nabriva Therapeutics Commends the CDC on the 2019 Antibiotic Resistance Threats Report, Highlighting the Need for New Antibiotics Aligned with Antibiotic Stewardship
S. pneumoniae continues to be designated by the CDC as “Serious Threat” underscoring need for rapid detection and prevention strategies, particularly in community setting XENLETA™ has a novel mechanism of action that is different than all other antibiotics, has been shown to be associated with a very low rate of resistance, and no cross resistance...
Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its third quarter financial results for the period ended September 30, 2019 and provided a business update.
X-Biotix Therapeutics Announces Corporate Progress and Successful Fundraise
Continued R&D progress on two candidate programs representing novel mechanism of action. Strengthens team with addition of industry veteran, Michael Bonney, as a Strategic Advisor. Obtains extension of Series A financing.